|Dr. Jan Schmidt-Brand||Chief Exec. Officer, Chief Financial Officer and Member of the Exec. Management Board||301.28k||N/A||59|
|Prof. Andreas Pahl||Chief Scientific Officer, Head of R&D and Member of the Exec. Mgmt Board||210.68k||N/A||N/A|
|Sylvia Wimmer||Mang. of Corp. Communications||N/A||N/A||N/A|
Wilex AG operates as a biopharmaceutical company that focuses on oncology and antibodies in Germany, rest of Europe, the United States, and internationally. Its product portfolio includes HDP-101, an antibody targeted amanitin conjugate (ATAC) candidate for the treatment of multiple myeloma; PSMA, an ATAC candidate to treat prostate cancer; CD19, an ATAC candidate for the treatment of haematological tumors; HuMAB 5B1, an ATAC candidate to treat metastatic pancreatic cancer; and NN, an ATAC candidate for treating leukemia. The companys product portfolio also comprise RENCAREX, a Phase III clinical trial product candidate for the treatment of clear cell renal cell carcinoma; REDECTANE, which has completed a Phase III trial for the treatment of kidney cancer; and MESUPRON that has completed Phase IIa clinical trials for the treatment of pancreatic and breast cancers. Wilex AG also provides preclinical contract services. The company was formerly known as WILEX Biotechnology GmbH and changed its name to Wilex AG in February 2001. Wilex AG was founded in 1997 and is headquartered in Munich, Germany.
Wilex AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.